Earnings ahead of profit

How did Anpario (LSE:ANP) lift adjusted Earnings per share by 30% in the first half of 2026 when profit before tax rose by 11%? The answer, according to the feed additives company's interim results, lies in a combination of share buybacks, adjustments for one-off costs and a lower tax rate on adjusted profits. This article explains those factors, the trading behind them and the risks the company has flagged for the second half.

What Anpario does

Anpario is quoted on AIM and describes itself as "the independent manufacturer of natural sustainable animal feed additives for animal health, nutrition and biosecurity". Its products are sold to livestock producers and feed manufacturers around the world, through direct sales teams and distributors. Leading brands include Orego-Stim, Optomega, pHorce and Mastercube, and the company also sells products through its Bio-Vet business. Richard Edwards is chief executive and Matthew Robinson is chairman.

The interim results

On 9 September 2026, Anpario reported results for the six months to 30 June 2026. Revenue rose 7% to £24.3m and Gross Profit increased 5% to £12.2m, with the gross Margin easing to 50.4% from 51.4%. Management said margins were broadly in line with the second half of 2025, crediting disciplined pricing that offset inflationary pressures. Adjusted EBITDA rose 22% to £5.0m and profit before tax increased 11% to £3.8m. Basic Earnings Per Share were 18.41p, up 13%, while diluted adjusted earnings per share rose 30% to 20.77p. The Interim Dividend was raised 6% to 3.8p.

The company attributed the faster growth in adjusted earnings per share to three factors: share Buybacks reducing the number of shares, the exclusion of £0.448m of non-recurring professional fees from adjusted profit, and a lower tax rate applied to adjusted profits.

The buyback and cash

Anpario completed a £3.0m buyback programme that began on 27 April 2026. According to its announcement of 27 July, it acquired 556,803 shares at an average price of 538.79p, with £2.1m spent during the half year. After cancellation, the company reported 20,039,026 shares in issue. Cash stood at £11.0m at 30 June 2026, compared with £12.4m at the end of 2025 and £11.1m a year earlier.

Regional and product trends

Performance varied by region. Sales in the IMEA region rose 56%, helped by new markets including Bahrain, Sudan and Morocco. The Americas grew 7%, with US sales up 19% offsetting weakness in Brazil and a transition to direct sales in Mexico. Asia fell 9%, which the company linked to weaker toxin binder sales (excluding toxin binders, Asia grew by 7%, according to the company), and Europe declined 2% despite UK growth of 28%. Leading brands, representing about 80% of sales, grew 17%, and the new product AmpLIPhy received first and repeat orders across multiple countries. Orego-Stim, Optomega, pHorce and Mastercube achieved record performances. Bio-Vet's QuadriCal bolus entered Middle Eastern markets during the period.

Risks and outlook

The company said the "impact from the ongoing Iran conflict is being felt the most across our Asia region", which has softened the start to the second half. Gross margin pressure from Inflation in acid-based eubiotics, which account for around 20% of sales, has been managed through pricing so far, but could persist. With the buyback complete, future earnings per share growth will depend more on underlying profit. The board said it expects second-half challenges to continue, while pointing to a healthy order pipeline. Chairman Matthew Robinson said geographic diversity and structural Demand drivers "position it well for continued sustainable growth".

Conclusion

Anpario's adjusted earnings per share outpaced profit growth because buybacks cut the share count, one-off fees were excluded and adjusted tax was lower. Underlying trading also improved, but conflict-related weakness in Asia is the main issue for the second half.